Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial

Affiliations

¹ Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, 27710, USA. andrew.armstrong@duke.edu.
² Division of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
³ Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea.
⁴ Scientia Clinical Research, Randwick, NSW, Australia.
⁵ Segal Cancer Center, McGill University, Jewish General Hospital, Montreal, QC, Canada.
⁶ Princess Margaret Cancer Centre, Toronto, ON, Canada.
⁷ Seoul National University Bundang Hospital, Gyeonggi-Do, South Korea.
⁸ Honor Health, Scottsdale, AZ, USA.
⁹ Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
¹⁰ Seoul National University Hospital, Seoul, South Korea.
¹¹ Center for Thoracic Oncology, Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA.
¹² Merck & Co., Inc, Rahway, NJ, USA.
¹³ Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA.

Published Erratum

Andrew J Armstrong et al. Invest New Drugs. 2024 Jun.

. 2024 Jun;42(3):340-341.

doi: 10.1007/s10637-024-01444-0.

¹ Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, 27710, USA. andrew.armstrong@duke.edu.
² Division of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
³ Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea.
⁴ Scientia Clinical Research, Randwick, NSW, Australia.
⁵ Segal Cancer Center, McGill University, Jewish General Hospital, Montreal, QC, Canada.
⁶ Princess Margaret Cancer Centre, Toronto, ON, Canada.
⁷ Seoul National University Bundang Hospital, Gyeonggi-Do, South Korea.
⁸ Honor Health, Scottsdale, AZ, USA.
⁹ Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
¹⁰ Seoul National University Hospital, Seoul, South Korea.
¹¹ Center for Thoracic Oncology, Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA.
¹² Merck & Co., Inc, Rahway, NJ, USA.
¹³ Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA.

No abstract available

Erratum for

CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
Armstrong AJ, Geva R, Chung HC, Lemech C, Miller WH Jr, Hansen AR, Lee JS, Tsai F, Solomon BJ, Kim TM, Rolfo C, Giranda V, Ren Y, Liu F, Kandala B, Freshwater T, Wang JS. Armstrong AJ, et al. Invest New Drugs. 2024 Feb;42(1):145-159. doi: 10.1007/s10637-023-01410-2. Epub 2024 Feb 7. Invest New Drugs. 2024. PMID: 38324085 Free PMC article. Clinical Trial.